TY - JOUR
T1 - Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine
AU - Wilder-Smith, Annelies
AU - Hombach, Joachim
AU - Ferguson, Neil
AU - Selgelid, Michael
AU - O'Brien, Kate
AU - Vannice, Kirsten
AU - Barrett, Alan
AU - Ferdinand, Elizabeth
AU - Flasche, Stefan
AU - Guzman, Maria
AU - Novaes, Hillegonde Maria
AU - Ng, Lee Ching
AU - Smith, Peter G.
AU - Tharmaphornpilas, Piyanit
AU - Yoon, In Kyu
AU - Cravioto, Alejandro
AU - Farrar, Jeremy
AU - Nolan, Terry M.
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/1
Y1 - 2019/1
N2 - The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.
AB - The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.
UR - http://www.scopus.com/inward/record.url?scp=85059232654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059232654&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(18)30494-8
DO - 10.1016/S1473-3099(18)30494-8
M3 - Review article
C2 - 30195995
AN - SCOPUS:85059232654
SN - 1473-3099
VL - 19
SP - e31-e38
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 1
ER -